The Blood Center in New Orleans has implemented Terumo Blood and Cell Technologies’ FDA-cleared automation technology to enhance platelet processing, becoming the second blood center in the U.S. to do so. This development aims to address ongoing platelet shortages and improve the efficiency of blood collection operations. The Reveos automation system from Terumo BCT is…more
Terumo Blood and Cell Technologies (Terumo BCT) is collaborating with Hemex Health to improve diagnosis and treatment for millions affected by sickle cell disease and other hemoglobin disorders. This partnership follows Terumo’s minority investment in Hemex Health and the appointment of Chetan Makam to Hemex’s Board of Directors. The collaboration aims to enhance access to…more
PharmaJet Inc. is expanding its needle-free injection technology by developing self-injection pens designed for home use. These pens will allow for precise administration of various pharmaceuticals without the need for traditional needles. The injectors are targeted at chronic disease and metabolic peptide markets and are currently undergoing early testing. By offering a needle-free option, PharmaJet…more
Kenya, Uganda, and Côte d’Ivoire have entered into a significant partnership with Terumo Blood and Cell Technologies to develop national frameworks for addressing sickle cell disease (SCD). This collaboration aims to tackle one of the most pressing public health challenges in Africa, where SCD accounts for a high rate of child mortality. The agreement, formalized…more
Aclarion Inc. has enrolled its first two patients at the UHealth – University of Miami Health System in its pivotal CLARITY trial. This randomized study is set to evaluate the ability of Nociscan to improve surgical outcomes for patients suffering from chronic low back pain. The CLARITY trial aims to assess the clinical and economic…more
CSL Plasma and Terumo Blood and Cell Technologies (Terumo BCT) have completed the nationwide rollout of a new plasma donation system across CSL Plasma centers in the United States. This milestone aims to enhance donor care and improve access to plasma-derived therapies for patients in need. The Rika Plasma Donation System, which has been installed…more
Terumo Blood and Cell Technologies (Terumo BCT) reported regulatory approvals in 14 Latin American countries for its Spectra Optia Apheresis System, allowing for new treatment options for sickle cell disease, Guillain-Barré syndrome and myasthenia gravis. This development signifies a major step toward enhancing access to therapies for patients with rare and chronic diseases in the…more
Aclarion Inc. has appointed Greg Gould as its new chief financial officer, effective immediately. Gould comes to Aclarion with more than 30 years of experience in public and private companies. He succeeds John Lorbiecki, who has announced his retirement after establishing a strong financial foundation for the company, Aclarion stated in a press release. Aclarion…more
Highridge Medical acquired several spine surgery products from Accelus, including the FlareHawk and Toro expandable interbody fusion systems and the LineSider pedicle screw system. The move is intended to strengthen Highridge’s presence in the growing market for expandable spinal implants. The acquired products feature proprietary designs, such as Accelus’s Adaptive Geometry, aimed at improving surgical…more
Terumo Blood and Cell Technologies (Terumo BCT) and PwC Belgium have partnered to improve access to advanced cell and gene therapies in Europe. This joint effort seeks to address existing barriers that prevent patients from receiving cutting-edge medical treatments. The partnership will kick off with an event in Brussels on Dec. 11, 2025, where industry…more
PharmaJet Inc. has been awarded a tender to support the first large-scale implementation of intradermal (ID) polio immunization in Afghanistan. The campaign, part of efforts to eradicate poliovirus in the region, is expected to begin in August 2025. The campaign will use Golden-based PharmaJet’s Tropis ID delivery system to administer fractional doses of inactivated polio…more
Ignite Proteomics, a subsidiary of IMAC Holdings, has announced a one-year collaboration with Vanderbilt University Medical Center (VUMC) aimed at enhancing the understanding of how breast cancer cells avoid detection by the immune system. This partnership will utilize VUMC’s clinical samples to characterize specific protein-signaling pathways associated with breast tumors. As part of the collaboration,…more